Clinicopathologic and Prognostic Implications of Programmed Death Ligand 1 Expression in Thymoma Presented at the Sixteenth World Conference on Lung Cancer, Denver, CO, September 6-9, 2015.

Annals of Thoracic Surgery

Volumn 101, Issue 4, 2016, Pages 1361-1369

  Yokoyama, Shintaro ^a   Miyoshi, Hiroaki ^a   Nishi, Tatsuya ^a   Hashiguchi, Toshihiro ^a   Mitsuoka, Masahiro ^a   Takamori, Shinzo ^a   Akagi, Yoshito ^a   Kakuma, Tatsuyuki ^b   Ohshima, Koichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MASAOKA STAGE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK ASSESSMENT; STAGING; THYMECTOMY; THYMOMA; TUMOR RECURRENCE; UNIVARIATE ANALYSIS; WORLD HEALTH ORGANIZATION; CANCER STAGING; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; THYMUS NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD274; ANTIGENS, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; ROC CURVE; THYMOMA; THYMUS NEOPLASMS;

EID: 84961217846     PISSN: 00034975     EISSN: 15526259     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2015.10.044     Document Type: Article

References (29)

1. A. Masaoka Staging system of thymoma J Thorac Oncol 5 10 Suppl 4 2010 S304 S312
2. M. Ried, H. Guth, T. Potzger, and et al. Surgical resection of thymoma still represents the first choice of treatment Thorac Cardiovasc Surg 60 2012 145 149
3. N. Girard, R. Lal, H. Wakelee, G.J. Riely, and P.J. Loehrer Chemotherapy definitions and policies for thymic malignancies J Thorac Oncol 6 7 Suppl 3 2011 S1749 S1755
4. J. Schmitt, and P.J. Loehrer Sr. The role of chemotherapy in advanced thymoma J Thorac Oncol 5 10 Suppl 4 2010 S357 S360
5. B.J. Chen, B. Chapuy, J. Ouyang, and et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies Clin Cancer Res 19 2013 3462 3473
6. A. Pedoeem, I. Azoulay-Alfaguter, M. Strazza, G.J. Silverman, and A. Mor Programmed death-1 pathway in cancer and autoimmunity Clin Immunol 153 2014 145 152
7. H. Dong, G. Zhu, K. Tamada, and L. Chen B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion Nat Med 5 1999 1365 1369
8. G.K. Philips, and M. Atkins Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies Int Immunol 27 2015 39 46
9. A. Gunturi, and D.F. McDermott Potential of new therapies like anti-PD1 in kidney cancer Curr Treat Options Oncol 15 2014 137 146
10. W.D. Travis, E. Brambilla, H.K. Muller-Hermelink, and C.C. Harris Pathology and genetics: tumours of the lung, pleura, thymus and heart 2004 IARC Press Lyon, France 145 247
11. M. Nagane, H. Yasui, T. Yamamori, and et al. Radiation-induced nitric oxide mitigates tumor hypoxia and radioresistance in a murine SCCVII tumor model Biochem Biophys Res Commun 437 2013 420 425
12. A.K. Akobeng Understanding diagnostic tests 3: receiver operating characteristic curves Acta Paediatr 96 2007 644 647
13. S. Muenst, S. Hoeller, S. Dirnhofer, and A. Tzankov Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival Hum Pathol 40 2009 1715 1722
14. N. Safieddine, G. Liu, K. Cuningham, and et al. Prognostic factors for cure, recurrence and long-term survival after surgical resection of thymoma J Thorac Oncol 9 2014 1018 1022
15. F. Detterbeck, S. Youssef, E. Ruffini, and M. Okumura A review of prognostic factors in thymic malignancies J Thorac Oncol 6 7 Suppl 3 2011 S1698 S1704
16. M. Okumura, M. Ohta, H. Tateyama, and et al. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients Cancer 94 2002 624 632
17. F. Granato, V. Blackhall, R. Alessandra, and et al. Outcome in excised thymomas: role of prognostic factors and impact of additional malignancies on survival Scott Med J 59 2014 22 29
18. F. Guerrera, E.A. Rendina, F. Venuta, and et al. Does the World Health Organization histological classification predict outcomes after thymomectomy? Results of a multicentre study on 750 patients Eur J Cardiothorac Surg 48 2015 48 54
19. R.K. Jain, R.J. Mehta, J.D. Henley, K.A. Kesler, P.J. Loehrer, and S. Badve WHO types A and AB thymomas: not always benign Mod Pathol 23 2010 1641 1649
20. T.T. Kuo, and J.K. Chan Thymic carcinoma arising in thymoma is associated with alterations in immunohistochemical profile Am J Surg Pathol 22 1998 1474 1481
21. Y. Zhang, L. Wang, Y. Li, and et al. Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma Onco Targets Ther 7 2014 567 573
22. S.K. Padda, J.W. Riess, E.J. Schwartz, and et al. Diffuse high intensity PD-L1 staining in thymic epithelial tumors J Thorac Oncol 10 2015 500 508
23. Y. Katsuya, Y. Fujita, H. Horinouchi, Y. Ohe, S. Watanabe, and K. Tsuta Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma Lung Cancer 88 2015 154 159
24. J. Oba, T. Nakahara, T. Abe, A. Hagihara, Y. Moroi, and M. Furue Expression of programmed death receptor ligand 1 in melanoma may indicate tumor progression and poor patient survival J Am Acad Dermatol 70 2014 954 956
25. J. Nakanishi, Y. Wada, K. Matsumoto, M. Azuma, K. Kikuchi, and S. Ueda Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers Cancer Immunol Immunother 56 2007 1173 1182
26. M.M. Mazanet, and C.C. Hughes B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis J Immunol 169 2002 3581 3588
27. H. Dong, S.E. Strome, D.R. Salomao, and et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nat Med 8 2002 793 800
28. D.D. Twa, F.C. Chan, S. Ben-Neriah, and et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma Blood 123 2014 2062 2065
29. J.A. Brown, D.M. Dorfman, F.R. Ma, and et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production J Immunol 170 2003 1257 1266